IFN-γ therapy has already been used as a treatment for pulmonary fibrosis [36] and may also be useful in a novel approach to the treatment of augmented fibrosis in the skin, such as hypertrophic scarring, keloid scarring and scleroderma. Here, IFNG is linked to scleroderma.